What is CVS Health's latest outlook for its full-year 2022 financial performance?

CVS Health reaffirmed its full-year 2022 Adjusted EPS guidance range of $8.55 to $8.65 and expects to report results at the high end of this range. The company also anticipates exceeding its revenue guidance of $309 billion to $314 billion, while reaffirming guidance for adjusted operating income and cash flow from operations.

What is the financial guidance for 2023, and does it include the Signify Health acquisition?

For 2023, CVS Health projected its Adjusted EPS guidance to be in the range of $8.70 to $8.90. This guidance specifically excludes any financial impact from the pending acquisition of Signify Health, Inc.

How did CVS Health manage its share count and capital allocation recently?

In the fourth quarter of 2022, CVS Health repurchased approximately 15 million shares. Additionally, the company entered into a $2.0 billion accelerated share repurchase transaction, which became effective on January 3, 2023, indicating a focus on returning capital to shareholders and reducing share count.

What is the update on CVS Health's Medicare Advantage (MA) and public health insurance exchange membership?

CVS Health expects low to mid-single digit percentage growth in total Medicare Advantage membership for 2023. While Individual MA enrollment during the annual period was below expectations, the company is experiencing strong growth in the dual-eligible special needs market. In contrast, their individual public health insurance exchange business exceeded expectations, with over 700,000 new members added this year, bringing total exchange membership to over 750,000 across 12 states.

CVS 8-K: Earnings & Results

Summary

CVS Health (CVS) has reaffirmed its full-year 2022 financial guidance, expecting Adjusted Earnings Per Share (EPS) to be at the high end of the previously stated $8.55 to $8.65 range. This outperformance is attributed to certain non-operating items, including a reduced share count. The company also anticipates exceeding its revenue guidance of $309 billion to $314 billion, while reaffirming its adjusted operating income and cash flow from operations guidance. Looking ahead to 2023, CVS Health reiterated its Adjusted EPS guidance of $8.70 to $8.90, notably excluding any impact from the pending Signify Health acquisition. The company's strategic initiatives, including share repurchases and expansion in public health insurance exchanges, are showing positive traction. Despite a slower-than-expected start in Individual Medicare Advantage enrollment, growth in other segments and strong performance in the health insurance exchange market suggest a robust outlook for the upcoming year.

Key Highlights

1Reaffirmed full-year 2022 Adjusted EPS guidance of $8.55-$8.65, expecting to finish at the high end.
2Expects to exceed full-year 2022 revenue guidance of $309-$314 billion.
3Reaffirmed full-year 2022 Adjusted Operating Income and Cash Flow from Operations guidance.
4Reiterated full-year 2023 Adjusted EPS guidance of $8.70-$8.90, excluding Signify Health acquisition impact.
5Completed $2.0 billion accelerated share repurchase program effective January 3, 2023.
6Expanded public health insurance exchange footprint to 12 states, adding over 700,000 new members.
7Acknowledged Individual Medicare Advantage enrollment came in below expectations for the 2023 annual enrollment period.

CVS HEALTH Corp 8-K Report, Financial Results (Jan 9, 2023)

Summary

Key Highlights

Frequently Asked Questions